VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Historical Holders from Q1 2014 to Q3 2025

Symbol: VRTX on Nasdaq
Type / Class: Equity / Common Stock
Shares outstanding: 256,606,920
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 231,629,792
Holdings value: $90,628,027,133
% of all portfolios: 0.04%
Number of holders: 1,490
Number of buys: 670
Number of sells: -761
Average buys %: +0.01%
Average sells %: -0.01%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
Capital World Investors	11.2%	$14,470,577,412	28,739,975	Capital World Investors	31 Dec 2024
Capital Research Global Investors	5.7%	$7,319,049,204	14,536,344	Capital Research Global Investors	31 Mar 2025
FMR LLC	3.6%	$4,642,686,284	9,220,826	FMR LLC	31 Dec 2024

Institutional Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	231,629,792	$90,628,027,133	-$3,690,940,692	$461,239,591	$711,553,846	$391.64	1,490
2025 Q2	240,735,835	$107,165,642,790	+$1,856,732,434	$493,290,312	$858,164,453	$445.2	1,543
2025 Q1	236,653,399	$114,743,267,144	+$569,969,794	$507,928,096	$659,725,474	$484.82	1,597
2024 Q4	236,056,630	$95,094,515,159	+$124,454,808	$577,997,207	$644,616,402	$402.7	1,542
2024 Q3	234,301,041	$108,951,765,309	-$108,863,209	$631,706,723	$731,988,295	$465.08	1,532
2024 Q2	234,132,938	$109,741,428,164	+$127,466,437	$738,983,992	$562,937,363	$468.72	1,538
2024 Q1	233,778,905	$97,614,728,920	-$351,588,308	$620,946,574	$559,847,135	$418.01	1,481
2023 Q4	234,732,281	$95,518,842,840	-$282,404,031	$691,414,908	$670,548,796	$406.89	1,430
2023 Q3	235,201,359	$81,839,440,920	-$491,731,898	$512,710,601	$532,146,469	$347.74	1,268
2023 Q2	236,903,503	$83,231,226,220	-$329,673,784	$320,698,800	$371,930,300	$351.91	1,270
2023 Q1	237,449,022	$74,800,726,409	+$551,796,768	$281,514,140	$349,705,514	$315.07	1,191
2022 Q4	237,264,020	$68,520,934,164	+$69,172,686	$284,060,662	$313,414,130	$288.78	1,206
2022 Q3	237,170,581	$68,704,605,708	+$746,235,756	$295,448,908	$353,070,074	$289.54	1,108
2022 Q2	234,049,687	$65,932,675,845	+$619,489,758	$334,208,358	$349,757,308	$281.79	1,093
2022 Q1	233,557,250	$60,872,369,529	+$1,115,223,036	$804,774,000	$516,646,968	$260.97	1,050
2021 Q4	229,577,277	$50,395,687,889	-$237,458,680	$459,131,000	$592,723,360	$219.6	1,015
2021 Q3	230,800,835	$41,840,598,359	-$222,800,189	$461,188,150	$429,029,287	$181.39	920
2021 Q2	232,062,084	$46,728,254,072	-$411,655,570	$608,998,750	$684,019,479	$201.63	961
2021 Q1	235,696,332	$50,611,371,510	-$676,555,551	$564,108,250	$522,205,070	$214.89	983
2020 Q4	238,859,796	$56,374,238,590	-$907,518,096	$320,596,000	$242,221,700	$236.34	952
2020 Q3	242,062,493	$65,824,669,920	-$146,259,561	$269,646,000	$249,446,000	$272.12	931
2020 Q2	242,428,011	$70,341,346,452	-$453,115,099	$312,192,000	$295,607,000	$290.31	949
2020 Q1	244,182,755	$58,075,410,564	+$196,877,946	$232,992,000	$263,288,000	$237.95	842
2019 Q4	243,469,587	$53,307,090,832	-$548,123,974	$327,534,000	$328,430,000	$218.95	801
2019 Q3	245,828,310	$41,645,081,563	+$11,091,504	$266,071,000	$215,825,000	$169.42	696
2019 Q2	245,761,916	$45,037,488,806	+$697,671,100	$239,164,000	$283,295,000	$183.38	706
2019 Q1	245,359,778	$45,126,400,894	+$339,461,201	$186,250,000	$220,091,000	$183.95	727
2018 Q4	243,404,158	$40,329,522,766	+$325,902,984	$340,949,000	$357,555,000	$165.71	690
2018 Q3	241,051,774	$46,450,620,394	+$73,088,499	$299,711,000	$327,561,000	$192.74	687
2018 Q2	241,039,338	$40,950,724,377	+$46,743,521	$255,411,000	$256,363,000	$169.96	682
2018 Q1	240,511,936	$39,191,663,333	+$165,476,417	$180,343,416	$190,004,198	$162.98	674
2017 Q4	239,681,066	$35,912,095,840	+$288,569,706	$151,967,726	$177,882,000	$149.86	637
2017 Q3	237,711,534	$36,110,677,595	+$313,167,858	$216,493,000	$289,546,000	$152.04	605
2017 Q2	236,016,217	$30,400,623,804	+$78,079,742	$116,589,000	$327,462,000	$128.87	569
2017 Q1	235,865,728	$25,790,913,428	+$2,166,564,931	$202,950,000	$210,176,000	$109.35	512
2016 Q4	236,349,218	$17,416,160,042	-$346,305,205	$85,360,000	$100,565,000	$73.67	470
2016 Q3	240,883,461	$20,998,584,687	+$86,246,858	$61,097,000	$67,637,000	$87.21	480
2016 Q2	239,982,115	$20,645,253,416	+$255,018,558	$51,369,000	$63,720,000	$86.02	473
2016 Q1	236,595,476	$18,805,795,173	-$180,672,437	$60,666,000	$45,100,000	$79.49	487
2015 Q4	234,502,647	$29,506,588,526	-$17,291,028	$103,458,000	$64,924,000	$125.83	510
2015 Q3	235,203,508	$24,493,775,645	+$667,231,333	$87,741,000	$56,307,000	$104.14	487
2015 Q2	230,096,138	$28,415,941,068	-$406,870,829	$102,518,000	$65,512,000	$123.48	496
2015 Q1	233,389,366	$27,539,570,108	+$443,200,071	$81,816,000	$64,509,000	$117.97	471
2014 Q4	229,712,105	$27,292,739,520	-$488,784,588	$402,986,000	$257,096,000	$118.8	467
2014 Q3	233,322,706	$26,203,942,928	+$763,613,344	$376,672,000	$262,550,000	$112.31	424
2014 Q2	227,000,681	$21,491,265,738	+$278,089,765	$591,872,000	$588,746,000	$94.68	405
2014 Q1	223,473,017	$15,797,763,300	+$100,431,175	$296,290,000	$191,508,000	$70.72	390